Background The effectiveness and safety of dabigatran etexilate (DE) have not been
elucidated thoroughly in clinical practice for Japanese patients with non-valvular atrial …

Background/aim A post‐marketing surveillance (PMS) study is being conducted to
investigate the safety and effectiveness of the long‐term use of dabigatran etexilate …

Background In “real-world” practice, anticoagulant therapy is indicated for patients whose
clinical profiles are not addressed in randomized clinical trials. We assessed the …

Dabigatran is an oral direct thrombin inhibitor (DTI), which has a rapid onset of action and
can be given twice daily (bid) without anticoagulation monitoring. To determine the long term …

Background—During follow-up of between 1 and 3 years in the Randomized Evaluation of
Long-term Anticoagulation Therapy (RE-LY) trial, 2 doses of dabigatran etexilate were …

Background: Dabigatran was shown effective for stroke prevention in atrial fibrillation (AF) in
RE-LY; and RELY-ABLE provided additional follow-up of dabigatran. Combining these two …

Background: RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) is an
international multicenter study (18,113 patients from 967 centers in 44 countries) that …

Background Idarucizumab, a dabigatran-specific reversal agent, was launched in Japan in
2016. The J-Dabigatran Surveillance 2 study was designed to assess the characteristics and …

The effectiveness and safety of dabigatran for stroke prevention in atrial fibrillation (SPAF)
demonstrated in RE-LY needs to be confirmed in daily care. To evaluate treatment …

Aims We aim to determine the optimal dose of dabigatran in Korean patients with atrial
fibrillation (AF). Methods and results We analysed 1834 patients with non-valvular AF …